Bans on smoking in public places were justified on the basis of limiting involuntary exposure to the hazards of second-hand smoke. On some levels, this seems to have worked; in areas where bans were implemented, cardiovascular events dropped by 15 percent, while hospital admissions for respiratory problems are down by a quarter.
But it’s hard to tell whether those benefits are being enjoyed by non-smokers who were exposed to second-hand smoke or smokers who cut back or quit in response to the inconveniences imposed by the new laws. Now, a recent study shows pretty definitively that non-smokers are benefitting, as improved health was seen in a population that clearly isn’t smoking: newborns and children.
Getting meta with smoking
The study, published in The Lancet, involved what’s called a meta-analysis. This technique involves identifying a collection of small studies that all meet a pre-determined standard for experimental rigor. The results of the studies are then pooled, providing a statistical rigor that the individual papers wouldn’t be able to reach. In this particular meta-analysis, the authors focused on three factors: rates of pre-term births, the weight of newborns, and hospitalization for asthma in children under 12.
In combination, the studies provided the meta-analysis with well over a million participants in the two questions related to births and 225,753 hospitalization cases for asthma in children. These came from a variety of countries; all of these restricted public smoking, but the details varied (some involved workplace smoking, others just bars and restaurants).
While birth weight showed an insignificant difference, there were clear health benefits for the other two issues. Preterm births dropped by more than 10 percent with the smoking ban, with the 95 percent confident interval ranging from two percent to 19 percent. For hospitalization due to asthma, the rate also dropped by 10 percent, and the 95 percent confidence interval was somewhat narrower (five to 15 percent).
The biggest limitation of the work is that it is largely limited to developed nations; very few bans, and even fewer studies, have been instituted in the industrializing world. It’s an open question whether the same benefits would be obtained in areas where access to healthcare isn’t uniform.